Interpretation of modified prescription for pharmacoeconomic analysis of New Zealand / 中国中药杂志
China Journal of Chinese Materia Medica
;
(24): 2840-2843, 2011.
Article
in Chinese
| WPRIM
| ID: wpr-293172
ABSTRACT
The Prescription for Pharmacoeconomic Analysis (PFPA) of New Zealand was firstly published in 1999. The original version was reviewed in 2004 and version 2, approved and published in 2007, is the living document. The main purpose for this guideline is to provide an overview of the methods PHARMAC (Pharmaceutical Management of Agency) uses when conducting cost-utility analysis. Compared with version 1, version 2 involved and discussed the most frequently mentioned issues in pharmacoeconomic guidelines around the world. This paper describes the distinguishes between version 1 and 2, the advantages of version 2 as well as the amendments that will be made in PHARMAC's future work, in order to provide meaningful advice for standardizing and documenting methods in China
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Economics, Pharmaceutical
/
Costs and Cost Analysis
/
New Zealand
Type of study:
Health economic evaluation
Limits:
Humans
Country/Region as subject:
Oceania
Language:
Chinese
Journal:
China Journal of Chinese Materia Medica
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS